Gastric cancer: Nagoya is not New York

Journal of Clinical Oncology

Volumn 29, Issue 33, 2011, Pages 4348-4350

  Macdonald, John S ^a  

^a Aptium Oncology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; GIMERACIL PLUS OTERACIL POTASSIUM PLUS TEGAFUR;

ASIA; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CAUCASIAN; COMPARATIVE STUDY; DRUG METABOLISM; EDITORIAL; GASTRECTOMY; HUMAN; JAPANESE; LYMPH NODE METASTASIS; MONOTHERAPY; MORBIDITY; NORTH AMERICA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHARMACOGENETICS; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); POSTOPERATIVE CARE; PRIORITY JOURNAL; RACE DIFFERENCE; STOMACH ADENOCARCINOMA; STOMACH CANCER; STOMACH CARCINOMA; SURVIVAL TIME; UNITED STATES; WESTERN EUROPE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; GASTRECTOMY; HUMANS; STOMACH NEOPLASMS;

EID: 81755171110     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.37.5691     Document Type: Editorial

References (15)

1. Garcia M, Jemal A, Ward EM, et al.: Global Cancer Facts & Figures 2007. Atlanta, GA: American Cancer Society
2. Jemal A, Siegel R, Xu J, et al.: Cancer Statistics 2010. CA Cancer J Clin 60:277-300, 2010
3. Macdonald J, Hundahl S, Smalley S, et al.: Gastric cancer, in Blanke CD, Rodel C, Talamonti MS (eds): Gastrointestinal Oncology: A Practical Guide-Heidelberg, Germany, Springer, 2010, pp 101-138
4. Macdonald JS, Smalley SR, Benedetti J, et al.: Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. N Engl J Med 345:725-730, 2001
5. Macdonald JS, Benedetti J, Smalley S, et al.: Chemoradiation of resected gastric cancer: A 10-year follow-up of the phase III trial INT0116 (SWOG 9008). J Clin Oncol 27:205s, 2009 (suppl; abstr 4515)
6. Cunningham D, Allum WH, Stenning SP, et al.: Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med 355:11-20, 2006
7. Ferly J, Shin H, Bray F, et al.: Cancer incidence and mortality worldwide: IARC CancerBase No. 10. http://globocan.iarc.fr
8. Kajitani T: The general rules for the gastric cancer study in surgery and pathology. Part I. Clinical classification. Jpn J Surg 11:127-139, 1981
9. Hartgrink HH, van de Velde CJ, Putter H, et al.: Extended lymph node dissection for gastric cancer: Who may benefit? Final results of the randomized Dutch Gastric Cancer Group trial. J Clin Oncol 22:2069-2077, 2004
10. Bunt AM, Hermans J, Smit VT, et al.: Surgical/pathologic-stage migration confounds comparisons of gastric cancer survival rates between Japan and Western countries. J Clin Oncol 13:19-25, 1995
11. Sasako M, Sakuramoto S, Katai H, et al.: Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387-4393, 2011
12. Shirasaka T, Shimamato Y, Ohshimo H, et al.: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-FU by two biochemical modulators. Anticancer Drugs 7:548-557, 1996 (Pubitemid 26276346)
13. Sakuramoto S, Sasako M, Yamaguchi T, et al.: Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810-1820, 2007 (Pubitemid 350044801)
14. Ohtsu A, Yoshida S, Saijo N: Disparities in gastric cancer chemotherapy between the east and west. J Clin Oncol 24:2188-2196, 2008
15. Ilson D: Just when you thought the fluorouracil debate was over: S-1 in gastric cancer. J Clin Oncol 25:6826-6836, 2005